COLONY STIMULATING FACTOR 1--REGULATION AND ROLE IN BONE
Project Number2R01DK045228-04
Former Number1R01AR041375-01
Contact PI/Project LeaderWEIR, ELEANOR C
Awardee OrganizationYALE UNIVERSITY
Description
Abstract Text
DESCRIPTION: (Adapted From Investigator's Abstract) The osteoblast, in
addition to forming bone, plays a central role in bone resorption.
Although the precise mechanism by which osteoblasts mediate osteoclastic
bone resorption is unclear, one widely held hypothesis is that in
response to bone resorbing agents, osteoblasts secrete cytokines which
activate osteoclasts or their precursors. While the nature of these
cytokines is unknown, one potential candidate is colony stimulating
factor-1 (CSF-1). There is substantial in vivo and in vitro evidence
that CSF-1 is critically important for both the proliferation and
differentiation of osteoclast progenitors: (1) deficiency of CSF-1 in
vivo causes osteopetrosis in the op/op mouse; (2) CSF-1 stimulates
osteoclast formation and bone resorption in vitro; and (3) CSF-1 is the
principal colony stimulating activity secreted by osteoblasts in response
to parathyroid hormone (PTH). Although there is mounting evidence for
osteoblast-derived CSF-1's role in osteoclast development, little is
known regarding the regulation of CSF-1 gene expression in osteoblasts,
or the isoforms of CSF-1 which are synthesized and secreted by
osteoblasts. In addition, the precise physiologic role of CSF-1 in
normal bone remodeling is poorly understood.
The applicants have recently demonstrated that tumor necrosis factor
(TNF) and PTH increase CSF-1 gene expression and protein release in
osteoblasts by a transcriptional mechanism. They plan to pursue these
observations by characterizing cis acting elements by which PTH and TNF
induce CSF-1 gene expression, and examining potential transcription
factors mediating this response, using a combination of deletional
analysis and nuclear protein-DNA binding studies. They have also
demonstrated by flow cytometry and by PCR analysis of reverse-
transcribed RNA that osteoblasts express a cell surface form of CSF-1,
which is increased by TNF treatment. They will, therefore, extend this
observation by examining the relative expression, regulation and
biological significance of the soluble and cell surface forms of CSF-1.
For these studies they will characterize the mRNA and protein species
of CSF-1 which are synthesized, processed and released by untreated and
TNF-treated osteoblasts, and will examine the effects of the soluble and
cell-surface forms of CSF-1 on osteoclast formation. Finally, they will
examine the role of CSF-1 in bone remodeling in vivo by developing and
analyzing a transgenic mouse with targeted over-expression of CSF-1 in
osteoblasts. Taken together, these studies should elucidate CSF-1's
regulation and role in bone and may improve the understanding of basic
mechanisms of bone resorption.
National Institute of Diabetes and Digestive and Kidney Diseases
CFDA Code
DUNS Number
043207562
UEI
FL6GV84CKN57
Project Start Date
01-February-1992
Project End Date
31-January-1999
Budget Start Date
01-February-1995
Budget End Date
31-January-1996
Project Funding Information for 1995
Total Funding
$168,305
Direct Costs
$102,625
Indirect Costs
$65,680
Year
Funding IC
FY Total Cost by IC
1995
National Institute of Diabetes and Digestive and Kidney Diseases
$168,305
Year
Funding IC
FY Total Cost by IC
Sub Projects
No Sub Projects information available for 2R01DK045228-04
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 2R01DK045228-04
Patents
No Patents information available for 2R01DK045228-04
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 2R01DK045228-04
Clinical Studies
No Clinical Studies information available for 2R01DK045228-04
News and More
Related News Releases
No news release information available for 2R01DK045228-04
History
No Historical information available for 2R01DK045228-04
Similar Projects
No Similar Projects information available for 2R01DK045228-04